Timing of androgendeprivation therapy for prostate cancer: still a long way to go
We read with interest the article in The Lancet Oncology by Gillian Duchesne and colleagues 1 on their study assessing the optimum timing (immediate vs delayed) of androgen-deprivation therapy for men with prostate cancer who have a rising concentration of prostate-specific antigen (PSA) even after curative therapy, or who are considered not suitable for curative treatment. This topic has a major impact on clinical practice, especially for patients affected by biochemical recurrence after local treatment, considering that approximately 30% of men experience a rise in PSA after both radical prostatectomy 2 and radiation therapy.
3 Although optimum timing of androgen-deprivation therapy has been assessed in previous clinical trials, 4 the novelty of Duchesne and colleagues' study lies in the assessment of asymptomatic patients only. However, the following points deserve discussion.
First, the group of patients eligible for the trial on the basis of PSA recurrence after curative treatment (radical prostatectomy alone, radiotherapy alone, or radical prostatectomy followed by salvage radiotherapy) included patients with extremely different disease stages, levels of disease progression, and prognoses. Moreover, asymptomatic patients unsuitable for curative treatment because of age and comorbidities were also included. Hence, the clinical heterogeneity within, and across groups, was extremely high, and the hypothesis of the study sounds unspecifi c and too vague for a randomised clinical trial.
Second, the investigators stratifi ed patients by type of previous treatment, relapse-free interval, PSA doubling time, androgen-deprivation therapy schedule, and metastases stage; however, tumour characteristics (such as tumour stage and Gleason score) were not taken into account although they represent well known prognostic factors for outcomes after radical prostatectomy, 2 radiotherapy, 3 and salvage radiotherapy. Third, Duchesne and colleagues concluded that immediate receipt of androgen-deprivation therapy significantly improved overall survival compared with delayed intervention. However, in the overall population the unadjusted hazard ratio (HR) for overall survival for immediate intervention versus delayed intervention was 0·55 (95% CI 0·30-1·00; p=0·050), which was not significant after adjusted Cox regression analysis (0·54, 0·27-1·06; p=0·074). Additionally, when considering the PSArelapse subpopulation only, no significant differences were noted between treatment groups for either the unadjusted HR (0·58, 95% CI 0·30-1·12; p=0·10) or the adjusted HR (0·59, 0·26-1·30; p=0·19). Furthermore, the survival difference became evident after at least 5 years, as patients unsuitable for curative treatment had a lower life expectancy because of age and comorbidities. Taken together, these fi ndings are far from proving a clear survival benefi t of immediate versus delayed androgen-deprivation therapy.
In conclusion, the results of Duchesne and colleagues' study should be interpreted with caution and contextualised on the basis of different clinical scenarios. Initial hypothesis, patient population, and randomisation type all play an essential role in the outcome of androgen-deprivation therapy, despite the high level of evidence from this randomised clinical trial.
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Authors' reply
We agree with Nicola Fossati and colleagues that the results of our trial 1 on the timing of androgen-deprivation therapy are not the final answer and need to be interpreted with some caution, accounting for the clinical characteristics of individual patients. Nonetheless, the trial has provided some useful evidence in a scenario where previously there was no evidence at all.
We do not agree with their interpretation of the three key limitations of the evidence. With respect to our trial design and patient stratification, a distinction needs to be made between prognostic factors at the time of diagnosis and those at the time of relapse, when patients have shown themselves to be high risk by not remaining in remission. First, the primary endpointprogression-free survival-was considered as a dichotomous outcome that included both biochemical and clinical recurrence-free survival, and cancer-specific and overall survival. Therefore, progression-free survival data from a patient who developed a rise in PSA after salvage radiotherapy was weighted equally with data from a patient who died from prostate cancer or other causes. This understanding is crucial to interpreting the data, since any significant difference between groups for progression-free survival might be related to the direct effect of hormonal therapy on PSA concentrations. Since a diff erence between groups in terms of metastatic progression was not noted, and there was no signifi cant difference between groups for 5-year overall survival (95% in the radiotherapy alone group vs 96% in the radiotherapy plus goserelin group; p=0·18), these findings are far from proving a clear benefit of adding short-term hormonal therapy to salvage radiotherapy.
Second, the dose of radiotherapy given to the prostate bed was 66 Gy, to the seminal vesicles was 50 Gy for pT3b disease only, and to the pelvis for patients with pNx disease (a risk of lymph-node invasion >15% according to the Partin table) was 46 Gy. The administered doses and areas chosen for radiation might have been appropriate for the recruitment period (2006-10) ; however, evidence is increasing that dose escalation might improve freedom from biochemical and clinical progression. Hence, the most important question is whether high-dose radiotherapy provides similar oncological outcomes to the results from Carrie and colleagues' study without the need for any additional hormonal therapy. If so, could patients be spared from systemic treatments with only a minor effect on their quality of life and without any additional costs? 4 This hypothesis is being investigated by the SAKK 09/10 trial (NCT01272050). Considering the results from Carrie and colleagues, this clinical question becomes highly relevant: in their study, among patients who had disease progression, 83% had local recurrence, suggesting suboptimum local control.
Third, limitations of the study included that the definition of the prostate bed was not clearly provided and no dummy-run exercises were done to quantify the effect of contouring variability. Therefore, important inter-institute variability might have occurred across the 43 centres involved, which could have aff ected the effi cacy of salvage radiotherapy.
5 Moreover, a central pathological review was not done, which might have aff ected the fi nal results because the pathological Gleason score was surprisingly not associated with the risk of disease progression after multivariable analysis.
In conclusion, the question of whether concomitant hormonal therapy should be administered with salvage radiotherapy remains. Results from ongoing trials are awaited to relapse (such as a prostate-specific antigen [PSA] doubling time of less than 3 months) were ineligible, and stratification included factors potentially relevant to subsequent characteristics such as relapse-free interval and PSA doubling time. The heterogeneity caused by including older patients who were not deemed suitable for curative treatment was recognised in the structure of the analysis, and they were ineligible for study entry if we estimated their life expectancy as less than 5 years.
With regards to our interpretation of the data, we were careful not to overemphasise their significance. The protocol-specified primary endpoint of overall survival was significantly improved with immediate receipt of androgendeprivation therapy compared with delayed intervention, but we did not claim significant differences in subsequent analyses, because we recognised that the power for these analyses was limited by the low numbers of patients recruited. Our interpretation was that the results were suggestive of a survival benefit with early intervention, they provided some evidence about possible benefits and detriments, and added weight to the concept that initiating treatment when disease volume is low might be more eff ective than later intervention.
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